报告发布方：中金企信国际咨询 中金企信自建数据库并搭建全路径数据矩阵，具备全球范围线上、线下数据资源约80亿条不同数据处理及背书能力。涉及900+行业统计/调研数据；5000万 +细分产品数据；450+项三方商业数据资源；1.5亿+国际贸易数据；20W+各领域企业监测数据等多位一体的完整数据源，切实做到数据有依据、数据有公信 力、数据有权威性、数据有合法性、数据有专业性的综合背书。中金企信自主搭建数据库及专业咨询团队，拥有中金企信独立的分析模型、调研体系、论证 体系、质量体系、售后体系等全套技术路线。同时与政界、学界、商界建立多位一体的综合资源路径，并具备外聘顾问智囊团队参与咨询技术路线制定和专 业评审，从咨询成果的质量方面、权威性方面、合法/合规性方面保障客户权益最大化。 （1）外周动脉球囊扩张导管行业基本概述：外周血管疾病指心血管和脑血管之外的所有周围血管疾病，可能由外周血管狭窄、阻塞或痉挛导致，患者大多 伴有多种危及健康的因素，包括高血压、高血糖、高血脂、高胆固醇、吸烟、家族心脏病史和年老等。外周血管疾病主要分为外周动脉疾病和外周静脉疾病 两大类。 外周动脉疾病是指因外周动脉局部狭窄或闭塞导致的身体局部 ...

Core Insights - The article highlights the significant benefits of Semaglutide for patients with type 2 diabetes and peripheral artery disease (PAD), emphasizing its ability to improve walking ability and quality of life without being affected by individual patient characteristics [8][19][20]. Group 1: Research Findings - Semaglutide shows a notable improvement in maximum walking distance (MWD) and pain-free walking distance (PFWD) for patients with symptomatic PAD, regardless of diabetes duration, BMI, or blood sugar control [10][12][13][14]. - The STRIDE trial included 792 patients with symptomatic PAD, demonstrating that all patient subgroups benefited from Semaglutide treatment [9][10]. - The study revealed that the improvement in walking ability was independent of weight loss and blood sugar control, suggesting a novel mechanism of action for Semaglutide [17][18]. Group 2: Clinical Implications - The findings indicate that Semaglutide can serve as a comprehensive treatment option for PAD in type 2 diabetes patients, enhancing lower limb blood circulation and functional capacity [20][21]. - The safety profile of Semaglutide was comparable to that of the placebo group, with no significant increase in adverse events, including hypoglycemia [18][19]. - This research opens new avenues for treating the challenging combination of diabetes and PAD, providing valuable clinical guidance [21].

Core Viewpoint - Semaglutide, a GLP-1 receptor agonist, shows significant benefits for patients with type 2 diabetes and peripheral artery disease (PAD), improving both walking distance and quality of life, beyond its glucose-lowering effects [3][10][13]. Research Objectives - The study aims to analyze the efficacy of semaglutide in improving functionality in type 2 diabetes patients with PAD, focusing on whether the effects are consistent across different clinical characteristics [5]. Research Methodology - The STRIDE trial included 792 patients with symptomatic PAD and type 2 diabetes, using a randomized, double-blind design over 52 weeks, comparing semaglutide treatment to a placebo [7]. Key Assessment Indicators - The primary endpoint was the improvement in maximum walking distance (MWD) after 52 weeks, with supplementary assessments on pain-free walking distance (PFWD) [9]. Research Results - Semaglutide significantly improved both MWD and PFWD across various patient characteristics, indicating a stable efficacy regardless of factors such as diabetes duration, body mass index (BMI), and blood glucose control [10][12]. - The average weight loss was 4.09 kg, and HbA1c levels decreased by 0.99%, but the benefits for PAD may operate through independent mechanisms [11][12]. Safety Profile - The safety of semaglutide was confirmed, with adverse event rates comparable to the placebo group, and no new safety concerns were identified [13]. Conclusion - Semaglutide is a promising treatment option for type 2 diabetes patients with PAD, demonstrating efficacy beyond traditional mechanisms, including improvements in endothelial function and microcirculation [16].